<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00462618</url>
  </required_header>
  <id_info>
    <org_study_id>H-19343</org_study_id>
    <nct_id>NCT00462618</nct_id>
  </id_info>
  <brief_title>Group Cognitive Behavioral Therapy (CBT I) Vs. Quetiapine for Residual Insomnia Impairing Recovery Among Elderly With Stable Major Affective Disorders</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael E. DeBakey VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Michael E. DeBakey VA Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot study is to assess feasibility and patient accessibility in order&#xD;
      to design an adequately powered study to compare group cognitive behavioral therapy for&#xD;
      insomnia (CBT-I) to quetiapine in non-demented patients aged 60 years or older with&#xD;
      controlled bipolar disorder (I or II) or major depressive disorder who suffer from residual&#xD;
      insomnia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PTSQ</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>CBT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine</intervention_name>
    <arm_group_label>CBT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cogntive behavioral therapy</intervention_name>
    <arm_group_label>CBT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age greater or equal to 60 years.&#xD;
&#xD;
          2. Patients with history of major affective disorder, including Bipolar disorder type I&#xD;
             or type II or major depressive disorder, as assessed by the Structured Clinical&#xD;
             Interview for DSM-IV (SCID), currently in remission.&#xD;
&#xD;
          3. Difficulty starting or initiating sleep four or more times/week for at least 3 months&#xD;
             by history.&#xD;
&#xD;
          4. Total Pittsburg Sleep Quality Index &gt;5.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient in an acute mood episode as assessed by SCID&#xD;
&#xD;
          2. Patients with sleep disruptive medical problems including: sleep apnea, restless leg&#xD;
             syndrome, periodic limb movement, parasomnia, congestive heart failure, chronic pain&#xD;
             and chronic obstructive pulmonary disease as assessed by medical history and medical&#xD;
             record review.&#xD;
&#xD;
          3. Patients with schizophrenia, primary anxiety disorder and active substance abuse as&#xD;
             determined by SCID.&#xD;
&#xD;
          4. Patients on or with history of failure or intolerance to respond to quetiapine.&#xD;
&#xD;
          5. Patient with positive Alcohol Use Disorders Identification Test (AUDIT) with a total&#xD;
             score above 8.&#xD;
&#xD;
          6. Patients with dementia brain degenerative diseases, cognitive disorders and Mini&#xD;
             Mental Status Examination (MMSE) score of less or equal to 24.&#xD;
&#xD;
          7. Patients who are in an acute depressive, manic, hypomanic or mixed state as reflected&#xD;
             by SCID&#xD;
&#xD;
          8. Patients on concurrent sedating medications that would confound interpretation of the&#xD;
             results. This is operationalized as follow: Sedating medications must be present and&#xD;
             stable dosage for at least 14 days prior to enrollment in the study. If the medication&#xD;
             is not prescribed as a primary sleep aid, it will be continued. Our rationale is that&#xD;
             patients may need these medications and the initial sedating effect will have&#xD;
             plateaued by 14 days. However, medications prescribed to assist insomnia will be&#xD;
             discontinued as they are not effective for the subjects who otherwise meet inclusion&#xD;
             ad exclusion criteria for the current study. Medications will be tapered as clinically&#xD;
             indicated after the patients sing informed consent and prior to baseline assessment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rayan k Al Jurdi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Michael Debakey VAMC, Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Michael Debakey VAMC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>April 18, 2007</study_first_submitted>
  <study_first_submitted_qc>April 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2007</study_first_posted>
  <last_update_submitted>April 22, 2013</last_update_submitted>
  <last_update_submitted_qc>April 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Michael E. DeBakey VA Medical Center</investigator_affiliation>
    <investigator_full_name>Rayan Al Jurdi, MD</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Insomnia</keyword>
  <keyword>Elderly</keyword>
  <keyword>Affective disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 24, 2014</submitted>
    <returned>April 23, 2014</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

